Zacks Investment Research upgraded shares of MediWound Ltd. (NASDAQ:MDWD) from a strong sell rating to a hold rating in a research note released on Wednesday.

According to Zacks, “MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel. “

Other equities research analysts have also recently issued reports about the stock. Aegis reissued a buy rating and issued a $11.00 price objective on shares of MediWound in a research report on Thursday, May 25th. Oppenheimer Holdings, Inc. set a $10.00 price objective on shares of MediWound and gave the company a buy rating in a research report on Monday, May 8th. Finally, SunTrust Banks, Inc. reissued a buy rating on shares of MediWound in a research report on Monday, June 26th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $10.19.

MediWound (NASDAQ MDWD) opened at 6.80 on Wednesday. MediWound has a 1-year low of $4.25 and a 1-year high of $8.58. The company has a 50-day moving average of $6.96 and a 200-day moving average of $6.41. The company’s market capitalization is $149.12 million.

MediWound (NASDAQ:MDWD) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.01. The company had revenue of $0.69 million during the quarter, compared to analysts’ expectations of $0.69 million. MediWound had a negative net margin of 752.78% and a negative return on equity of 240.54%. MediWound’s quarterly revenue was up 93.8% on a year-over-year basis. During the same period last year, the firm earned ($0.34) earnings per share. Equities analysts expect that MediWound will post ($0.82) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “MediWound Ltd. (MDWD) Upgraded at Zacks Investment Research” was first posted by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/08/05/mediwound-ltd-mdwd-upgraded-at-zacks-investment-research.html.

Several large investors have recently bought and sold shares of MDWD. Renaissance Technologies LLC raised its stake in MediWound by 1.7% in the first quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 1,300 shares in the last quarter. Wells Fargo & Company MN raised its position in MediWound by 19.7% in the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 8,745 shares during the period. Finally, Wellington Management Group LLP raised its position in MediWound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock valued at $14,241,000 after buying an additional 213,745 shares during the period. Institutional investors and hedge funds own 27.32% of the company’s stock.

About MediWound

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Get a free copy of the Zacks research report on MediWound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.